Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-02-14
2000-04-25
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540145, 540122, 549385, 549282, 514410, 514455, 514461, A61K 3141, C07D47822, C09B 4700
Patent
active
06054449&
ABSTRACT:
A broad class of photosensitive compounds having enhanced in vivo target tissue selectivity and versatility in photodynamic therapy. Many furocoumarin compounds, such as psoralens, exhibit cytostatic activity when photoactivated but exhibit little in vivo specificity for selectively accumulating in any particular target tissue such as atheromatous plaques. Reactive Oxygen Producing Photosensitizers ("ROPPs") are photoactivatable compounds having an affinity for hyperproliferating cells (such as atheromatous plaque cells), which when photoactivated, produce cytotoxic reaction products. The photoactivity of a ROPP, such as a porphyrin, may be reduced by metalating the porphyrin while the selective affinity of the metalized ROPP for hyperproliferating tissue remains substantially unchanged. By linking a furocoumarin compound to a ROPP to form a F-ROPP, the cytostatic properties of the furocoumarin portion of the F-ROPP can be exploited while the selective affinity of the ROPP portion of the compound for hyperproliferating cells such as atheromatous plaque provides enhanced tissue selectivity without cytotoxicity. In vivo, certain F-ROPPs may be forced to selectively accumulate in a target tissue by illuminating only the target tissue with light having a wavelength operable for photoactivating the F portion of the F-ROPP thereby causing the F-ROPP to either form a monoadduct with or crosslink the cellular DNA in the target tissue. Light of a second wavelength can then be delivered to the target tissue to photoactivate the ROPP portion causing further interference with cellular activity.
REFERENCES:
patent: 5736563 (1998-04-01), Richter
Joshi et al., J. Invst. Dermatol (1984) 82-(1) 67-73.
Hradecna et al., Acta Virology., (1982) 26(5)., 305-11.
Dall 'Acqua et al. B.B.A., 1974, 353(3) 267-73 Also only Abs are available.
Morgan Alan R.
Narciso, Jr. Hugh L.
Robinson Byron
Miravant Pharmaceuticals, Inc.
Shah Mukund J.
Sripada Pavanaram K.
LandOfFree
Compounds and method for PDT of intimal hyperplasia and other di does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and method for PDT of intimal hyperplasia and other di, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and method for PDT of intimal hyperplasia and other di will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-993520